Using these approaches, we provided evidence that variations in phosphoinositide secondary messenger signalling pathway, and for the first time, that the PLEKHA5 and PLCXD3 genes, might confer vulnerability to early-onset BD. The gene discussed is PLEKHA5; the disease is Behcet disease.